BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen JJ, Chan P, Paes B, Mitchell I, Li A, Lanctôt KL; CARESS investigators. Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention. PLoS One 2015;10:e0134711. [PMID: 26237402 DOI: 10.1371/journal.pone.0134711] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Butt ML, Elliott L, Paes BA. Respiratory syncytial virus hospitalization and incurred morbidities the season after prophylaxis. Paediatr Child Health 2018;23:441-6. [PMID: 30374219 DOI: 10.1093/pch/pxy046] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Karampatsas K, Kong J, Cohen J. Bronchiolitis: an update on management and prophylaxis. Br J Hosp Med (Lond) 2019;80:278-84. [PMID: 31059347 DOI: 10.12968/hmed.2019.80.5.278] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
3 Li A, Wang DY, Lanctôt KL, Mitchell I, Paes BA. Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005–2015). Pediatric Infectious Disease Journal 2017;36:445-50. [DOI: 10.1097/inf.0000000000001357] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
4 Hervé PL, Dhelft V, Zuniga A, Ghasparian A, Rassek O, Yim KC, Donne N, Lambert PH, Benhamou PH, Sampson HA, Mondoulet L. Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus. Vaccine 2021;39:4555-63. [PMID: 34154864 DOI: 10.1016/j.vaccine.2021.03.081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Manzoni P, Paes B, Lanctôt KL, Dall'Agnola A, Mitchell I, Calabrese S, Maule M, Girardi E, Harimoto T, Li A. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study. Pediatr Infect Dis J 2017;36:2-8. [PMID: 27649365 DOI: 10.1097/INF.0000000000001340] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
6 Lim A, Butt ML, Dix J, Elliott L, Paes B. Respiratory syncytial virus (RSV) infection in children with medical complexity. Eur J Clin Microbiol Infect Dis 2019;38:171-6. [PMID: 30374685 DOI: 10.1007/s10096-018-3409-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
7 Gülsen A, Wedi B, Jappe U. Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events. Allergo J 2020;29:32-61. [PMID: 32546899 DOI: 10.1007/s15007-020-2550-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
8 Simões EAF, Bont L, Manzoni P, Fauroux B, Paes B, Figueras-Aloy J, Checchia PA, Carbonell-Estrany X. Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children. Infect Dis Ther 2018;7:87-120. [PMID: 29470837 DOI: 10.1007/s40121-018-0188-z] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 14.0] [Reference Citation Analysis]
9 González-Parra G, Dobrovolny HM. Modeling of fusion inhibitor treatment of RSV in African green monkeys. J Theor Biol 2018;456:62-73. [PMID: 30048719 DOI: 10.1016/j.jtbi.2018.07.029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
10 Gülsen A, Wedi B, Jappe U. Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events. Allergo J Int 2020;29:97-125. [PMID: 32421085 DOI: 10.1007/s40629-020-00126-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
11 Wang DY, Li A, Paes B, Mitchell I, Lanctôt KL; CARESS Investigators. First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015). Eur J Pediatr 2017;176:413-22. [PMID: 28105526 DOI: 10.1007/s00431-017-2849-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
12 Rey-Jurado E, Kalergis AM. Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine Design. Int J Mol Sci 2017;18:E556. [PMID: 28273842 DOI: 10.3390/ijms18030556] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]